Ocular Therapeutix
OCUL
90 hedge funds and large institutions have $141M invested in Ocular Therapeutix in 2020 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 26 increasing their positions, 21 reducing their positions, and 13 closing their positions.
452% more call options, than puts
Call options by funds: $2.95M | Put options by funds: $535K
92% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 13
42% more capital invested
Capital invested by funds: $99.6M → $141M (+$41.4M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
24% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 21
14% more funds holding
Funds holding: 79 → 90 (+11)
1.75% more ownership
Funds ownership: 52.42% → 54.17% (+1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SR
Summer Road
West Palm Beach,
Florida
|
+$7.16M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$4.94M |
| 3 |
Millennium Management
New York
|
+$4.83M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
+$1.71M |
| 5 |
EGI
EAM Global Investors
Solana Beach,
California
|
+$1.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
-$3M |
| 2 |
MWP
MYCIO Wealth Partners
Philadelphia,
Pennsylvania
|
-$1.06M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$732K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$572K |
| 5 |
Morgan Stanley
New York
|
-$437K |
OCUL Hedge Fund Activity: Q1 2020 in Review
90 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q1 2020, worth a combined $141M — up 42% from $99.6M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new OCUL positions and 13 closed out — a net gain of 12 holders — while 26 added to existing stakes and 21 trimmed.
The largest buyer was Summer Road, adding an estimated $7.16M. The largest seller was Man Group, exiting entirely with an estimated $3M sold.
- 90 institutional investors held Ocular Therapeutix (OCUL) as of Q1 2020, up from 79 in Q4 2019.
- Funds reported $141M of Ocular Therapeutix stock for Q1 2020, up 42% quarter-over-quarter.
- 25 funds opened new Ocular Therapeutix positions in Q1 2020 and 13 closed out, a net change of +12 holders.
- The largest Ocular Therapeutix buyer in Q1 2020 was Summer Road, an estimated $7.16M added.
- The largest Ocular Therapeutix seller in Q1 2020 was Man Group, an estimated $3M sold.
Based on aggregated 13F filings for Q1 2020.